Glenn Bubley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Glenn Bubley has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
A S Kibel
Department of Surgery (Division of Urology), Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts, USA
1 shared publicationJerry Kao
Department of Pathology, Divisions of Oncology and Urology, Beth Israel Deaconess Medical Center, Boston, Massachusetts
1 shared publicationPing L. Zhang
Department of Laboratory Medicine, Geisinger Health System, Danville, Pennsylvania, USA
1 shared publicationRavindra Veeramachaneni
Department of Pathology, Louisiana State University Health Sciences Center, Shreveport, Louisiana
1 shared publicationSeymour Rosen
Department of Pathology, Divisions of Oncology and Urology, Beth Israel Deaconess Medical Center, Boston, Massachusetts
1 shared publicationT M Downs
1 shared publication
Latest Publications
- 15 October 2002
- Published by Wiley in The Prostate
- Vol. 53 (3) , 179-182
Association between prostate cancer and serum testosterone levels
BACKGROUND: The purpose of the current study was to determine whether the presence of prostate cancer altered serum testosterone levels.METHODS: Initially, we evaluated both serum total and free testosterone levels in patients with either high‐grade (n = 18) or moderate‐grade (n = 146) prostate cancer, detected by prostate needle biopsies. Then both serum total and free testosterone levels, before and after prostatectomy, were compared in 79 of the 164 men with prostate cancer.RESULTS: In the first setting, serum total and free testosterone levels (307 ± 24 ng/dl and 1.14 ± 0.09 ng/dl) in patients with high‐grade prostate cancer were significantly lower than those in patients with moderate‐grade prostate cancer (452 ± 12 ng/dl and 1.51 ± 0.04 ng/dl) and those without prostate cancer (451 ± 17 ng/dl and 1.55 ± 0.06 ng/dl). After prostatectomy in 79 patients with prostate cancer, serum levels of both total and free testosterone (511 ± 15 ng/dl and 1.78 ± 0.05 ng/dl) were found significantly elevated when compared with their respective presurgical total and free testosterone levels (450 ± 17 ng/dl and 1.60 ± 0.06 ng/dl).CONCLUSION: Our findings show that serum total and free testosterone levels in patients with prostate cancer are altered, supporting the possibility that prostate cancer may inhibit serum testosterone levels. Prostate 53: 179–182, 2002.
- 15 October 2002
- Published by Wiley in The Prostate
- Vol. 53 (3) , 179-182
Association between prostate cancer and serum testosterone levels
BACKGROUND: The purpose of the current study was to determine whether the presence of prostate cancer altered serum testosterone levels.METHODS: Initially, we evaluated both serum total and free testosterone levels in patients with either high‐grade (n = 18) or moderate‐grade (n = 146) prostate cancer, detected by prostate needle biopsies. Then both serum total and free testosterone levels, before and after prostatectomy, were compared in 79 of the 164 men with prostate cancer.RESULTS: In the first setting, serum total and free testosterone levels (307 ± 24 ng/dl and 1.14 ± 0.09 ng/dl) in patients with high‐grade prostate cancer were significantly lower than those in patients with moderate‐grade prostate cancer (452 ± 12 ng/dl and 1.51 ± 0.04 ng/dl) and those without prostate cancer (451 ± 17 ng/dl and 1.55 ± 0.06 ng/dl). After prostatectomy in 79 patients with prostate cancer, serum levels of both total and free testosterone (511 ± 15 ng/dl and 1.78 ± 0.05 ng/dl) were found significantly elevated when compared with their respective presurgical total and free testosterone levels (450 ± 17 ng/dl and 1.60 ± 0.06 ng/dl).CONCLUSION: Our findings show that serum total and free testosterone levels in patients with prostate cancer are altered, supporting the possibility that prostate cancer may inhibit serum testosterone levels. Prostate 53: 179–182, 2002.
- 1 October 1996
- Vol. 156 (4) , 1436
Squamous cell carcinoma of the renal pelvis with inferior vena caval extension.
- 1 October 1996
- Vol. 156 (4) , 1436
Squamous cell carcinoma of the renal pelvis with inferior vena caval extension.